Clifford Martin, MD
Infectious Disease · Tucson, AZNPI 1760429864
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $689 of the $775 with a category attached, or 88.9%. It is spread thinly across 12 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $317 and has fallen 93.2% since, to $22 in 2025.
Across 40 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$147
- Astellas Pharma US Inc$113
- Viiv Healthcare Company$81
- Aimmune Therapeutics, Inc.$75
- Paratek Pharmaceuticals, Inc.$74
- Tetraphase Pharmaceuticals, Inc.$69
- plus $216 from 6 others
What the payments were for
- Food & beverage$68989%
- Education$8611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 8 | $147 |
| Astellas Pharma US Inc | 5 | $113 |
| Viiv Healthcare Company | 4 | $81 |
| Aimmune Therapeutics, Inc. | 2 | $75 |
| Paratek Pharmaceuticals, Inc. | 4 | $74 |
| Tetraphase Pharmaceuticals, Inc. | 4 | $69 |
| Gilead | 4 | $61 |
| Merck | 3 | $48 |
| Johnson & Johnson | 2 | $42 |
| Cumberland Pharmaceuticals, Inc. | 2 | $33 |
| Insmed, Inc. | 1 | $16 |
| Nabriva Therapeutics, PLC | 1 | $16 |
How this compares
$775 in reported general payments places this provider in the 65th percentile of 146 infectious disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tigecycline | 47 | $68,598 |
| Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium | 60 | $25,365 |
| Daptomycin | 37 | $7,548 |
| ErtapenemErtapenem Sodium | 13 | $4,401 |
| CeftriaxoneCeftriaxone Sodium | 14 | $3,164 |
| Cefazolin Sodium | 39 | $2,006 |
| Meropenem | 11 | $1,613 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Tucson
- Mohanad Al-ObaidiTucson$3K
- Logan FelixTucson$2K
- Sudha NagalingamTucson$2K
- Marcelo NasifTucson$1K
- Richard MandelTucson$1K
- Steven OscherwitzTucson$1K
- Laura ValdiviaTucson$1K
- Vimbai NyembaTucson$806
- Janin StrumingerTucson$805
- Angelita Poston-SeitzTucson$770
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.